State Street Corp Acquires 145,400 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

State Street Corp increased its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 28.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 664,621 shares of the biopharmaceutical company’s stock after acquiring an additional 145,400 shares during the period. State Street Corp’s holdings in Sangamo Therapeutics were worth $576,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SGMO. Renaissance Technologies LLC lifted its position in shares of Sangamo Therapeutics by 58.8% during the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after purchasing an additional 1,528,600 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares in the last quarter. Marshall Wace LLP boosted its position in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares during the period. FMR LLC grew its stake in Sangamo Therapeutics by 16.5% in the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after acquiring an additional 77,032 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its position in shares of Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 241,440 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on SGMO. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Wells Fargo & Company cut their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Jefferies Financial Group lowered their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Friday, December 13th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO opened at $1.30 on Friday. The company’s 50-day simple moving average is $2.13 and its 200-day simple moving average is $1.23. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The stock has a market capitalization of $271.24 million, a P/E ratio of -1.73 and a beta of 1.15.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period last year, the firm earned ($0.34) earnings per share. On average, research analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.